Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04584710 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
A Phase 2 study of Covid19, sponsored by Restorbio.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT04584710 is a Phase 2 study of Covid19 that is active but no longer recruiting, run by Restorbio. The registered enrollment target is 60 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04584710, a Phase 2 study of Covid19, is active but no longer recruiting, sponsored by Restorbio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RTB101
Study Locations (2)
Connecticut
- University of Connecticut, UConn Center on Aging - Farmington
Massachusetts
- Hebrew Senior Life, Marcus Institute for Aging Research - Roslindale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2021-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04584710
The ClinicalTrials.gov registry entry for NCT04584710 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The listed sponsor is Restorbio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04584710 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04584710 about?
NCT04584710 is a clinical study titled "A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults". The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.
What is the current status of trial NCT04584710?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-10-13. Estimated completion is 2021-02.
What conditions does trial NCT04584710 study?
This clinical trial studies the following conditions: Covid19.
What interventions are being tested in trial NCT04584710?
The interventions under investigation include: Placebo (DRUG), RTB101 (DRUG).
Who is sponsoring clinical trial NCT04584710?
This trial is sponsored by Restorbio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04584710 being conducted?
This trial has 2 study locations across Connecticut, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
Defibrotide for the Treatment of Severe COVID-19
RECRUITING · Phase 2
-
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
ACTIVE NOT RECRUITING · Phase 2
-
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
ACTIVE NOT RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.